According to the World Health Organization (WHO), we are rapidly approaching a 'post-antibiotic' era. The knowledge gap about antibiotic resistance and room for progress is evident and unified combating strategies to mitigate the inadvertent trends of resistance seem to be lacking. Doxycycline remains a valuable antimicrobial agent by virtue of its potent microbiological profile, anti-inflammatory and immunomodulatory activity, and practical advantages like cost-effectiveness and ease of availability. Indian clinicians may like to consider doxycycline optimally for effective infection care. This may help Indian healthcare system, in defying the massive battle against anti-microbial resistance.
President Heart Care Foundation of India and Group Editor in Chief MEDtalks
Recipient of Padma Shri, Vishwa Hindi Samman, National Science Communication Award and Dr B C Roy National Award, Dr Aggarwal is a physician, cardiologist, spiritual writer and motivational speaker. He was the Past President of the Indian Medical Association and President of Heart Care Foundation of India. He was also the Editor in Chief of the IJCP Group, Medtalks and eMediNexus
Distinguished Professor, Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi
Dr Shyam Sundar, MD, FRCP (London), FAMS, FNASc, FASc, FNA, Distinguished Professor, Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi.
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Your privacy is important to us
MEDICAL AFFAIRS
CONTENT INTEGRITY
NEWSLETTERS
© 2022 Medtalks
